RxDoctor Payments Data

Ioannis Kehagias, MD

Family Medicine · Middletown, DENPI 1497839419

Payments from drug & device makers

$954in general payments, 2019–2025

Across 56 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$189
  • Novo Nordisk$138
  • AstraZeneca$117
  • Lilly USA, LLC$111
  • Genentech USA, Inc.$80
  • GSK$65
  • plus $256 from 9 others

What the payments were for

  • Food & beverage$94999%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$954 in reported general payments places this provider in the 65th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$243,140
Medicare patients
779
Services billed
2,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$210,613
MounjaroTirzepatide50$62,306
JardianceEmpagliflozin42$62,121
EliquisApixaban51$58,397
TrulicityDulaglutide40$57,860
XareltoRivaroxaban41$51,841
FarxigaDapagliflozin Propanediol32$46,249
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$38,319
JanuviaSitagliptin Phosphate18$25,369
VascepaIcosapent Ethyl21$17,485
Ezetimibe335$14,717
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$12,616
Breo ElliptaFluticasone/Vilanterol16$11,816
Atorvastatin Calcium700$10,354
Icosapent Ethyl15$9,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$138$210,613149 claims
Lilly USA, LLCMounjaro, Trulicity$111$120,16590 claims
Boehringer IngelheimJardiance$20$62,12142 claims
PfizerEliquis$26$58,39751 claims
Johnson & JohnsonXarelto$189$51,84141 claims
GSKTrelegy Ellipta, Breo Ellipta$65$50,13557 claims
AstraZenecaFarxiga$117$46,24932 claims
MerckJanuvia$22$25,36918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 352 family medicine providers in Delaware.

Other family medicine in Middletown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →